Factors Affecting Topical Treatment Success in Pediatric Scabies Cases: A Cross-Sectional Study
Keywords:
children, , permethrin, scabies, sulfur, treatmentAbstract
Introduction: Scabies is a common disease affecting the pediatric population. Treatment failure and relapses are frequent.
Objectives: We aimed to define factors affecting topical treatment success in pediatric scabies patients.
Methods: This multicenter cross-sectional study was performed between April and December 2022. Pediatric scabies cases were classified as treatment failure (TF) versus treatment success (TS).
Results: We enrolled 170 patients in the study. In the TF group, the presence of symptomatic household members and referral from physicians other than dermatologists were more common (both p<0,001) and relapse rates and total symptom duration were higher (p=0,007, p<0,001 respectively). Permethrin 5% was more commonly used in the TF group (71.1% versus 25%) (p<0,001); however, the ratio of patients treated with sulfur preparations was significantly higher in the TS group (60.7% vs 16.9%) (p<0,001). Misapplication of topical therapy was significantly more common in the TF group (p<0,001), statistically significant errors being: (i) lack of treatment of close contacts (p<0,001); (ii) single application (p<0,001); and (iii) local application (p=0,027). In a multivariate analysis, treatment success was mainly associated with (i) presence of atopy (O.R.: 5,29, 95% CI: 1,22-25,57) ;(ii) absence of symptomatic household members (O.R.: 5,29, 95% CI: 1,72-16,27); (iii) presentation to dermatologists rather than other specialties (O.R.: 6,08, 95% CI: 1,9-19,51); whereas use of permethrin negatively affected treatment success (O.R: 0,22, 95% CI: 0,07-0,71).
Conclusions: Pediatric scabies patients should be treated before other family members get affected and with topicals other than permethrin. Awareness of scabies disease needs to be increased among non-dermatologists.
References
Sunderkötter C, Wohlrab J, Hamm H. Scabies: Epidemiology, Diagnosis, and Treatment. Dtsch Arztebl Int. 2021;118(41):695-704. DOI: 10.3238/arztebl.m2021.0296. PMID: 34615594. PMCID: PMC8743988.
Özden MG, Ertürk K, Kartal SP, et al. An extraordinary outbreak of scabies in Turkey. J Eur Acad Dermatol Venereol. 2020;34(12), e818-e820. DOI: 10.1111/jdv.16699. PMID: 32491243.
Aussy A, Houivet E, Hébert V, et al. Risk factors for treatment failure in scabies: a cohort study. Br J Dermatol. 2019;180(4):888-893. DOI: 10.1111/bjd.17348. PMID: 30376179.
Lassa S, Campbell MJ, Benett CE. Epidemiology of scabies prevalence in the U.K. from general practice records. Br J Dermatol. 2011;164(6):1329–1334. DOI: 10.1111/j.1365-2133.2011.10264.x. PMID: 21574970.
Lee SK, Kim JH, Kim MS, Lee UH. Risk factors for scabies treatment resistance: a retrospective cohort study. J Eur Acad Dermatol Venereol. 2022;36(1):126-132. DOI: 10.1111/jdv.17713. PMID: 34592030.
Albakri L, Goldman RD. Permethrin for scabies in children. Can Fam Physician. 2010;56(10):1005-1006. PMID: 20944041. PMCID: PMC2954078.
Tripathi R, Knusel KD, Ezaldein HH, Bordeaux JS, Scott JF. Emergency Department Visits due to Scabies in the United States: A Retrospective Analysis of a Nationally Representative Emergency Department Sample. Clin Infect Dis. 2020;70(3):509-517. DOI: 10.1093/cid/ciz207. PMID: 30874793.
Sunderkötter C, Feldmeier H, Fölster‐Holst R, et al. S1 guidelines on the diagnosis and treatment of scabies – short version. J Dtsch Dermatol Ges. 2016;14(11):1155-1167. DOI: 10.1111/ddg.13130. PMID: 27879074.
Yürekli A. Is there a really resistance to scabies treatment with permethrin? In vitro killing activity of permethrin on Sarcoptes scabiei from patients with resistant scabies. Dermatol Ther. 2022;35(3):e15260. DOI: 10.1111/dth.15260. PMID: 34897912.
Mayer KE, Biedermann T, Posch C. European scabies challenge: what about permethrin-resistant mites? Eur Acad Dermatol Venereol. 2022;36(9):e712-e713. DOI: 10.1111/jdv.18181. PMID: 35470925.
Mazzatenta C, Piccolo V, Argenziano G, Bassi A. Is Scabies becoming less sensitive to permethrin therapy? J Eur Acad Dermatol Venereol. 2021;35(9):e607-e609. DOI: 10.1111/jdv.17339. PMID: 33974300.
Bassi A, Piccolo V, Mazzatenta C. One-shot" combined therapy with oral ivermectin and local benzyl benzoate: is the current best therapeutic option in the era of permethrin resistant scabies? Travel Med Infect Dis. 2023;53:102585. DOI: 10.1016/j.tmaid.2023.102585. PMID: 37149241.
Bassi A, Piccolo V, Argenziano G, Mazzatenta C. Topical ivermectin: an off-label alternative to treat neonatal Scabies in the era of permethrin resistance. J Eur Acad Dermatol Venereol. 2022;36(7):e557–9. DOI: 10.1111/jdv.18026. PMID: 35188996.
Nemecek R, Stockbauer A, Lexa M, Poeppl W, Mooseder G. Application errors associated with topical treatment of scabies: an observational study. J Dtsch Dermatol Ges. 2020;18(6):554-559. DOI: 10.1111/ddg.14122. PMID: 32469466.
De Sainte Marie B, Mallet S, Gaudy-Marqueste C, et al. Gales en échec de traitement : étude observationnelle [Therapeutic failure in scabies: An observational study]. Ann Dermatol Venereol. 201;143(1):9-15. DOI: 10.1016/j.annder.2015.10.588. PMID: 26651923.
Published
Issue
Section
License
Copyright (c) 2023 Muazzez Çiğdem Oba, Defne Özkoca, Rana Başara Şahin, Didem Şenses Kazan, Gaye Guldiken, Beril Kara Esen

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Dermatology Practical & Conceptual applies a Creative Commons Attribution License (CCAL) to all works we publish (http://creativecommons.org/licenses/by-nc/4.0/). Authors retain the copyright for their published work.

